Clark & Stuart Inc Sells 5,877 Shares of Stryker Corporation $SYK

Key Points

• Clark & Stuart Inc has decreased its stake in Stryker Corporation by 39.9%, selling 5,877 shares, resulting in a holding of 8,834 shares valued at approximately $3.5 million.
• Stryker reported a 12.25% net margin and earned $3.13 per share in its latest quarterly earnings, surpassing estimates, with revenues reaching $6.02 billion.
• The company announced a quarterly dividend of $0.84 per share, reflecting an annualized dividend of $3.36 and a yield of 0.9%, which will be paid on October 31st.

Clark & Stuart Inc lowered its position in Stryker Corporation (NYSE:SYK - Free Report) by 39.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,834 shares of the medical technology company's stock after selling 5,877 shares during the quarter. Stryker accounts for about 2.6% of Clark & Stuart Inc's holdings, making the stock its 16th largest position. Clark & Stuart Inc's holdings in Stryker were worth $3,502,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Country Club Bank lifted its position in Stryker by 0.5% in the second quarter. Country Club Bank now owns 6,103 shares of the medical technology company's stock worth $2,402,000 after purchasing an additional 29 shares during the period. Trueblood Wealth Management LLC increased its holdings in Stryker by 8.4% in the 2nd quarter. Trueblood Wealth Management LLC now owns 4,358 shares of the medical technology company's stock valued at $1,724,000 after buying an additional 336 shares during the period. KPP Advisory Services LLC raised its stake in shares of Stryker by 17.2% in the 2nd quarter. KPP Advisory Services LLC now owns 1,318 shares of the medical technology company's stock valued at $521,000 after buying an additional 193 shares in the last quarter. Capital Advisors Inc. OK lifted its holdings in shares of Stryker by 3.0% during the 2nd quarter. Capital Advisors Inc. OK now owns 155,031 shares of the medical technology company's stock worth $61,335,000 after acquiring an additional 4,502 shares during the period. Finally, Comprehensive Financial Consultants Institutional Inc. boosted its position in shares of Stryker by 0.6% during the 2nd quarter. Comprehensive Financial Consultants Institutional Inc. now owns 4,546 shares of the medical technology company's stock valued at $1,799,000 after acquiring an additional 28 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 1.2%

Shares of NYSE SYK opened at $365.99 on Tuesday. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The firm's 50-day simple moving average is $382.13 and its 200 day simple moving average is $378.92. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company has a market cap of $139.92 billion, a price-to-earnings ratio of 48.48, a price-to-earnings-growth ratio of 2.67 and a beta of 0.94.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter last year, the company posted $2.81 EPS. The company's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's payout ratio is 44.50%.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 500 shares of the business's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. BTIG Research reissued a "buy" rating on shares of Stryker in a report on Monday, July 14th. Needham & Company LLC boosted their price target on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Evercore ISI upped their price target on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Finally, Rothschild Redb raised Stryker to a "hold" rating in a report on Thursday, September 18th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.